**Flex Pharma Presenting at Upcoming Investor Conferences in June 2017**

[Click to Tweet](http://ctt.ec/Jbpe9)

May 30, 2017

Boston, MA - Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Charcot-Marie-Tooth (CMT), today announced that it will present at the following upcoming investor conferences in June:

* The Jefferies Global Healthcare Conference on June 6, 2017 at 2:30 pm ET in New York, NY;
* The JMP Securities Life Science Conference on June 20, 2017 at 2:00 pm ET in New York, NY.

A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at [www.flex-pharma.com](http://www.flex-pharma.com). Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma’s website for 2 weeks following each presentation.

**About Flex Pharma**

Flex Pharma, Inc. is a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with the severe neurological diseases including ALS, MS and Charcot-Marie-Tooth (CMT). Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair and CEO Christoph Westphal, M.D., Ph.D.

###

Contact:

Elizabeth Woo

SVP, Investor Relations & Corporate Communications

Flex Pharma, Inc.

irdept@flex-pharma.com

617-874-1829